Global Sarcopenia Market

Sarcopenia Market Valued at USD 2.89 Bn in 2023, Expected to Reach USD 4.23 Bn by 2030 with a 5.6% CAGR

Sarcopenia Market Overview:

Sarcopenia is a condition where older people lose their muscle mass and strength as they age, causing problems like falling down, breaking bones, becoming disabled, and even death. Sarcopenia generally starts to happen in the 40s, and it continues to get worse as one gets older. By the time person reach the 80s,may have lost about half of muscle mass. Sarcopenia can be caused by things like getting older, not being active, having chronic diseases, or not eating well.Sarcopenia results in a bad quality of life as well as disability.

Sarcopenia has no definitive cure, there are several treatments that slow down the disease and improve quality of life. Along with aging sarcopenia is also associated with several health problems such as Heart disease, Strokes, and cancer. Musculoskeletal conditions are increasing day by day worldwide. A recent publication by WHO states that 1.71 billion people have musculoskeletal conditions globally,driving the Sarcopenia market.

Sarcopenia Market Scope and Research Methodology:

 The Sarcopenia Market report offers a brief overview of the global Sarcopenia market. The report insights into growth factors, limitations, and emerging market trends in the industry. The report provides a segmentation of the Sarcopenia market by treatment type, route of administration, distribution channel and end-user market, and region. Primary research includes interviews with market experts, clinicians, and patients, and secondary research involving data collected from publications, government websites, and other sources. The collected data was analysed using statistical tools such as descriptive statistics and forecasting models.The Sarcopenia Market report also provides information about the leading players in the market, their business overview, financial overview, and recent developments.To know about the Research Methodology :- Request Free Sample Report

Sarcopenia Market Dynamics:

Drivers:

Rising Awareness of Sarcopenia Among Medical Professionals and The General Public

Sarcopenia is a medical condition that is prevalent as the global population ages. By 2030, around 1 in 6 people in the world will be 60 years old or older, according to a recent report by the World Health Organization. Rising awareness of Sarcopenia among medical professionals and the general public is driving the market growth. People are becoming more aware of Sarcopenia and its symptoms, such as reduced muscle mass and strength, as well as decreased physical performance. Early diagnosis and treatment of Sarcopenia lead to improve quality of life and reduce the progression of the disease. Increased awareness is driving demand for Sarcopenia diagnostic procedures and treatments, thereby contributing to the growth of the market.

Restraints:

High Cost of Treatment is a Significant Barrier to Sarcopenia Market

The high cost of treatment is a major challenge for patients, as protein supplements and resistance training, which are common therapies are expensive and unaffordable for those with limited financial means. The lack of appropriate curative therapy for sarcopenia hinders market growth, as there are currently no approved muscle-building agents available. Non-drug therapies like exercise and lifestyle modifications are the primary methods used, but they do not provide a complete solution. Diagnosing sarcopenia can be complex and require specialized tools that may not be widely accessible, leading to under diagnosis and delayed treatment.

Treatment options, such as nutritional supplements and pharmacological interventions are costly, especially in the long term, posing a noteworthy restraint for individuals without adequate healthcare coverage. Regulatory hurdles in the development and approval of drugs targeted for sarcopenia can cause delays in market entry. The coexistence of sarcopenia with other age-related conditions also presents challenges in managing multiple conditions simultaneously. Lastly, limited scientific knowledge and ongoing research gaps impede the development of targeted interventions, impacting the market's growth.

Sarcopenia Market Segment Analysis:

Based on treatment type,the protein supplements segment is expected to be the growing segment of the market. This is due to the increasing awareness of the importance of protein for muscle health.In addition to traditional protein supplements, there are also emerging therapies that utilize novel protein sources. For example, a new study published in April 2022 is investigating the role of Blue Whiting protein hydrolysates combined with physical exercise help to improve overall body lean mass and muscle strength in elderly free-living communities.Based on End-user market segmented into Hospitals are expected to drive the market due to the high prevalence of Sarcopenia among hospitalized patients. Many patients in hospitals, especially older individuals or those with underlying health conditions, experience muscle loss due to factors like extended bed rest or limited mobility. Hospitals have specialized departments and healthcare professionals experienced in dealing with geriatric conditions, offering comprehensive medical services, diagnostic tests, therapies, and surgeries if needed.

Clinics, specializing in geriatric care or musculoskeletal health, are also significant in the Sarcopenia market. These clinics provide outpatient services, focusing on early detection, diagnosis, and treatment of Sarcopenia

Healthcare settings beyond hospitals and clinics, such as rehabilitation centers, nursing homes, assisted living facilities, and home healthcare services, form another end-user segment. This segment is expected to grow rapidly, driven by the increasing number of individuals with Sarcopenia receiving treatment at home.

Sarcopenia Market Regional Insights:

North America is dominating the Sarcopenia market in 2023 and is expected to continue its dominance during the forecast period. This is mainly due to the high occurrence of Sarcopenia among the elderly population in the region, along with the increasing healthcare spending and the presence of key players in the market. North America benefits from advanced healthcare facilities and a growing awareness of the disease among healthcare professionals and patients.

Asia-Pacific region is expected to have rapid growth in the Sarcopenia market. This can be attributed to the increasing number of elderly individuals, a rise in healthcare expenditure, and the presence of several pharmaceutical companies catering to market demands. Followed by Europe, the Middle East, and South America are also expected to experience substantial growth, with a fast Compound Annual Growth Rate (CAGR). This is primarily driven by the ageing population in these regions, which necessitates the development of solutions and treatments for Sarcopenia.

Competitive Landscape for Sarcopenia Market: 

The Sarcopenia Market is highly competitive and key companies are investing significant resources in research and development to create novel and innovative therapies. These companies are competing in terms of product quality, price, and innovation, driving the growth of the market. For instance, in 2022, Bayer AG introduced its novel concept of Healthy Aging, which has aimed the transforming ageing with health innovation.In addition to developing new drugs, companies are expanding their product through acquisitions and mergers. This led to the introduction of a number of new and innovative products in the market. Sanofi S.A., Glaxo Smith Kline plc., Novartis AG, Pfizer Inc., Asta Real AB, Merck Sharp & Dohme Corp., AbbVie Inc. and Amgen Inc. are some major key players in Sarcopenia market.

Sarcopenia Market Scope: Inquire before buying

Sarcopenia Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Sarcopenia Market Key Players

1. Bayer AG
2. Zydus Cadila
3. GlaxoSmithKline plc
4. Nestle Health Science
5. Sanofi S.A.
6. GlaxoSmithKline plc.
7. Novartis AG
8. Pfizer Inc.
9. AstaReal AB
10. Merck Sharp & Dohme Corp.
11. AbbVie Inc.
12. Abbott laboratories, Inc.
13. American Way (Amway) Corporation
14. F-Hoffmann La-Roche
15. Amgen Inc.
16. Johnson & Johnson

FAQs:

1. What is the growth rate of the Sarcopenia Market?
Ans. Sarcopenia Market is expected to grow by 5.6%.

2. What segments are covered in the Sarcopenia Market report?
Ans. The segments covered are treatment type, Route of Administration, Distribution channel, End-users and region.

3. What are the key driving factors for the growth of the Sarcopenia Market?
Ans. Increasing healthcare expenditures and the growing geriatric population will likely accelerate the growth of the Sarcopenia Market.

4. Which segments dominate the Sarcopenia market growth?
Ans. Treatment dominates the Sarcopenia Market Growth over the forecast period.

5. Which region has the largest share in Sarcopenia Market?
Ans. North America holds the highest share in 2023.